Adjuvant and additive therapy for cancer of the pancreas

JP Neoptolemos, MGT Raraty, P Chaneh, H Hickey, Deborah Stocken, Janet Dunn, H Friess

Research output: Contribution to journalArticle

10 Citations (Scopus)


Recent advances have been made in the treatment of pancreas cancer. Specialized pancreas centres have reported an increasing rate of resections with reduced postoperative mortality. On account of the highly aggressive nature of pancreas cancer, there is a great challenge in identifying effective therapy concepts for advanced stages of the cancer as well as for the development of resection-associated measures. As large-scale, randomised, controlled studies are lacking, the additive therapy concepts after resection do not have a sufficiently scientific basis. The ESPAC-1 study, which included 600 patients, surpassed all previous studies on adjuvant therapy for pancreas cancer. This study has shown,for example, that the most promising adjuvant chemotherapy with 5-fluorouracil and folic acid leads to an equal if not better result than the multimodal regimen. This regimen can be superseded with the use of Gemcitabine, which will be evaluated in the ESPAC-3 study that includes 990 patients from various European countries including Germany, as well as from Canada and Australia. Participation in the large, phase-3 study therefore plays a key role in the continued development of the management of pancreas cancer.
Original languageEnglish
Pages (from-to)191-201
Number of pages11
Publication statusPublished - 1 Jan 2003


Dive into the research topics of 'Adjuvant and additive therapy for cancer of the pancreas'. Together they form a unique fingerprint.

Cite this